Whereas the serum FABP4 levels were found to be inversely associated with liver steatosis in a study performed in an elderly population (> 65 years) [111], others have shown increased serum FABP4 levels in non-elderly MAFLD patients [20,21,22,23,24,25,30,112,113]. This evidence concerns the gene FABP4 and fatty liver disease.